实体器官恶性肿瘤对急性缺血性卒中患者住院结局与复发的影响
基于美国全国再入院数据库2016至2018年数据,共纳入1,385,840例急性缺血性卒中住院患者,其中50,553例(3.7%)合并实体器官恶性肿瘤。校正基线差异后,恶性肿瘤患者住院死亡风险更高(OR 2.15,95%CI 2.04-2.28),1年内因复发性卒中再入院风险亦更高(HR 1.18,95%CI 1.11-1.25),该风险主要由肺癌和胰腺癌驱动。
要点
- 合并实体器官恶性肿瘤的急性缺血性卒中患者住院死亡风险约为无恶性肿瘤者的2.15倍(OR 2.15,95%CI 2.04-2.28)。
- 恶性肿瘤患者接受静脉溶栓的可能性更低,接受机械取栓的可能性更高。
- 合并肺癌或胰腺癌的患者1年内复发性卒中再入院风险更高(HR 1.18,95%CI 1.11-1.25)。
核心结论
- 合并恶性肿瘤的急性缺血性卒中患者住院结局总体更差,但不同癌症类型及是否接受急性卒中干预之间存在显著差异。
- 对于符合条件的合并恶性肿瘤患者,静脉溶栓和机械取栓总体是安全的。
- 肺癌和胰腺癌患者早期复发卒中风险更高,作者认为可能需要更密切的监测和审慎制定最佳二级预防措施。
研究设计与样本
- 回顾性队列研究,数据来源于2016至2018年美国全国再入院数据库(Nationwide Readmissions Database)。
- 共纳入1,385,840例以急性缺血性卒中为主要诊断的成人住院患者,平均年龄70.4±14.0岁,女性占50.2%。
- 其中50,553例(3.7%)合并实体器官恶性肿瘤诊断。
主要发现
- 最常见的5种恶性肿瘤依次为肺癌(24.6%)、前列腺癌(13.2%)、乳腺癌(9.3%)、胰腺癌(6.5%)和结直肠癌(6.2%)。
- 校正基线差异后,恶性肿瘤患者发生脑实质出血的OR为1.11(95%CI 1.04-1.19),住院死亡的OR为2.15(95%CI 2.04-2.28),出院去向非回家的OR为1.70(95%CI 1.64-1.75)。
- 恶性肿瘤患者接受静脉溶栓(组织型纤溶酶原激活剂[tPA])的可能性更低,接受机械取栓(MT)的可能性更高。
- 在接受tPA或MT治疗的亚组中,合并与不合并恶性肿瘤患者的结局相当,但肺癌患者在接受这些急性卒中干预后仍具有更高的死亡和不良出院去向风险。
- 恶性肿瘤患者出院后1年内因复发性急性缺血性卒中再入院的HR为1.18(95%CI 1.11-1.25),该风险由肺癌和胰腺癌驱动。
临床怎么用
- 对于符合条件的合并恶性肿瘤的急性缺血性卒中患者,静脉溶栓和机械取栓总体是安全的。
- 作者认为,肺癌和胰腺癌患者可能需要更密切的监测和审慎制定最佳二级预防措施。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The aim of this work was to evaluate the influence of solid organ malignancies on the in-hospital outcomes and recurrent strokes among patients hospitalized with acute ischemic stroke (AIS). METHODS: Adult hospitalizations with a primary diagnosis of AIS were identified from the Nationwide Readmissions Database from 2016 to 2018. Logistic regression was used to compare the differences in the use of acute stroke interventions and clinical outcomes in patients with and without malignancy. Survival analysis was used to evaluate the risk of readmission due to recurrent stroke after discharge. RESULTS: There were 1,385,840 hospitalizations due to AIS (mean ± SD age 70.4 ± 14.0 years, female 50.2%). Of these, 50,553 (3.7%) had a concurrent diagnosis of solid organ malignancy. The 5 most common malignancies included lung cancer (24.6%), prostate cancer (13.2%), breast cancer (9.3%), pancreatic cancer (6.5%), and colorectal cancer (6.2%). After adjustment for baseline differences, patients with malignancy were more likely to have intraparenchymal hemorrhage (odds ratio [OR] 1.11, 95% CI 1.04-1.19), in-hospital mortality (OR 2.15, 95% CI 2.04-2.28), and discharge disposition other than to home (OR 1.70, 95% CI 1.64-1.75). Patients with malignancy were less likely to receive IV thrombolysis (tissue plasminogen activator [tPA]) and were more likely to undergo mechanical thrombectomy (MT). Among the subgroups of patients treated with tPA or MT, the outcomes were comparable between patients with and without malignancy, except patients with lung cancer remained at a higher risk of mortality and adverse disposition despite these acute stroke interventions. Patients with malignancy were at a higher risk of readmission due to recurrent AIS within 1 year of discharge (hazards ratio 1.18, 95% CI 1.11-1.25), and this risk was driven specifically by the lung and pancreatic cancers. DISCUSSION: While patients with malignancy generally have worse in-hospital outcomes compared to those without, there is considerable variation in these outcomes according to the different cancer types and the use of acute stroke interventions. The use of tPA and MT is generally safe for eligible patients with an underlying malignancy. Patients with lung and pancreatic cancers have a higher early risk of recurrent stroke and might need more intensive surveillance and careful institution of the optimal secondary prevention measures.
引用
- Garg A, Chopra S, Starr M, et al. In-Hospital Outcomes and Recurrence of Acute Ischemic Stroke in Patients With Solid Organ Malignancy. Neurology. 2022. PMID: 35487697. doi:10.1212/WNL.0000000000200601
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。